Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus

Endocrine Practice

Volumn 18, Issue 3, 2012, Pages 418-424

  Kaiserman, Kevin ^a   Rodriguez, Henry ^b   Stephenson, Amanda ^c   Wolka, Linda ^c   Fahrbach, Jessie L ^d  

^a SoCal Diabetes   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Lilly USA   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN LISPRO;

ADOLESCENT DISEASE; CHILDHOOD DISEASE; CONTINUOUS INFUSION; CROSSOVER PROCEDURE; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

ADOLESCENT; CHILD; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN LISPRO;

EID: 84861023653     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11265.RA     Document Type: Review

References (38)

1. The effect of intensive treatment of diabetes on the devel-opment and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
2. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
3. Heinemann L, Woodworth J. Pharmacokinetics and glucodynamics of insulin lispro. Drugs of Today. 1998 34:23-36.
4. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396-402.
5. Anderson JH Jr, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insu-lin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med. 1997;157:1249-1255.
6. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treat-ment. Multicenter Insulin Lispro Study Group. Diabetes. 1997;46:265-270.
7. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F; European Society for Paediatric Endocrinology; Lawson Wilkins Pediatric Endocrine Society; International Society for Pediatric and Adolescent Diabetes; American Diabetes Association; European Association for the Study of Diabetes. Use of insu-lin pump therapy in the pediatric age-group: Consen-sus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2007;30:1653-1662.
8. Cohen D, Weintrob N, Benzaquen H, Galatzer A, Fayman G, Phillip M. Continuous subcutaneous insulin infusion versus multiple daily injections in adolescents with type I diabetes mellitus: A randomized open crossover trial. J Pediatr Endocrinol Metab. 2003;16:1047-1050.
9. DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr. 2004;145:380-384.
10. Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P. Use of insulin pump therapy at nighttime only for chil-dren 7-10 years of age with type 1 diabetes. Diabetes Care. 2000;23:579-582.
11. Pozzilli P, Crinò A, Schiaffini R, et al; IMDIAB Group. A 2-year pilot trial of continuous subcutaneous insulin infu-sion versus intensive insulin therapy in patients with newly diagnosed type 1 diabetes (IMDIAB 8). Diabetes Technol Ther. 2003;5:965-974.
12. Schiaffini R, Patera PI, Bizzarri C, Ciampalini P, Cappa M. Basal insulin supplementation in type 1 diabetic chil-dren: A long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin. J Endocrinol Invest. 2007;30:572-277.
13. Shashaj B, Busetto E, Sulli N. Benefits of a bolus calcula-tor in pre- And postprandial glycaemic control and meal flex-ibility of paediatric patients using continuous subcutaneous insulin infusion (CSII). Diabet Med. 2008;25:1036-1042.
14. Tubiana-Rufi N, Coutant R, Bloch J, et al. Special man-agement of insulin lispro in continuous subcutaneous insu-lin infusion in young diabetic children: A randomized cross-over study. Horm Res. 2004;62:265-271.
15. Weintrob N, Benzaquen H, Galatzer A, et al. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabe-tes: A randomized open crossover trial. Pediatrics. 2003; 112:559-564.
16. Weinzimer SA, Ternand C, Howard C, Chang CT, Becker DJ, Laffel LM; Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insu-lin lispro in children and adolescents with type 1 diabetes. Diabetes Care. 2008;31:210-215.
17. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center ran-domized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005;28: 15-19.
18. Ahern JA, Boland EA, Doane R, et al. Insulin pump ther-apy in pediatrics: A therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes. 2002;3:10-15.
19. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infu-sion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in ado-lescents with type 1 diabetes. Diabetes Care. 1999;22: 1779-1784.
20. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and pre-school children with type 1 diabetes mellitus. J Pediatr. 2002;141:490-495.
21. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP. Continuous subcutaneous insulin infusion therapy for children and adolescents: An option for routine diabetes care. Pediatrics. 2001;107:351-356.
22. Pankowska E, Skórka A, Szypowska A, Lipka M. Memory of insulin pumps and their record as a source of information about insulin therapy in children and ado-lescents with type 1 diabetes. Diabetes Technol Ther. 2005;7:308-314.
23. Ramchandani N, Ten S, Anhalt H, et al. Insulin pump therapy from the time of diagnosis of type 1 diabetes. Diabetes Technol Ther. 2006;8:663-670.
24. Sulli N, Shashaj B. Long-term benefits of continuous sub-cutaneous insulin infusion in children with type 1 diabetes: A 4-year follow-up. Diabet Med. 2006;23:900-906.
25. Alemzadeh R, Ellis JN, Holzum MK, Parton EA, Wyatt DT. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regi-men using insulin glargine in type 1 diabetes. Pediatrics. 2004;114:e91-e95.
26. Berhe T, Postellon D, Wilson B, Stone R. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: A retrospective study. Pediatrics. 2006;117:2132-2137.
27. Conrad SC, McGrath MT, Gitelman SE. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr. 2002; 140:235-240.
28. Danne T, Battelino T, Jarosz-Chobot P, et al; PedPump Study Group. Establishing glycaemic control with con-tinuous subcutaneous insulin infusion in children and ado-lescents with type 1 diabetes: Experience of the PedPump Study in 17 countries. Diabetologia. 2008;51:1594-1601.
29. Hanas R, Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increas-ing the risk of hypoglycemia [Erratum in: Pediatr Diabetes. 2006;7:298
30. Pediatr Diabetes. 2006;7:25-31.
31. Liberatore R Jr, Perlman K, Buccino J, Artiles-Sisk A, Daneman D. Continuous subcutaneous insulin infusion pump treatment in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2004;17:223-226.
32. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26: 1142-1146.
33. Rami B, Nachbaur E, Waldhoer T, Schober E. Continuous subcutaneous insulin infusion in toddlers. Eur J Pediatr. 2003;162:721-722.
34. Schiaffini R, Ciampalini P, Spera S, Cappa M, Crinó A. An observational study comparing continuous subcuta-neous insulin infusion (CSII) and insulin glargine in chil-dren with type 1 diabetes. Diabetes Metab Res Rev. 2005; 21:347-352.
35. American Diabetes Association. Standards of medi-cal care in diabetes-2011. Diabetes Care. 2011;34(Suppl 1):S11-S61.
36. Rewers M, Pihoker C, Donaghue K, Hanas R, Swift P, Klingensmith GJ. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2009;10(Suppl 12):71-81.
37. Wolpert HA, Faradji RN, Bonner-Weir S, Lipes MA. Metabolic decompensation in pump users due to lispro insulin precipitation. BMJ. 2002;324:1253.
38. Kerr D, Morton J, Whately-Smith C, Everett J, Begley JP. Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continu-ous subcutaneous insulin infusion catheters using low flow rates. J Diabetes Sci Technol. 2008;2:450-455.